The POWER1 study evaluating the efficacy of vormatrigine in patients with focal onset seizures failed to meet its primary success measure. As a result, Praxis has paused enrollment in the POWER2 study to reassess the vormatrigine program and determine potential modifications. However, higher doses (30 mg) showed a more pronounced reduction in seizures, and the drug was generally well-tolerated.
A Delaware district court ruled Heron's CINVANTI patent claims invalid, potentially opening the door for generic competition from Azurity Pharmaceuticals.
Read the full storyThe FDA issued a Complete Response Letter for CTx-1301, focusing on manufacturing controls rather than clinical safety or efficacy.
Crescita Therapeutics confirmed a final cash payment of $0.80 per share for its shareholders following the successful completion of its merger with ClinActiv Holdings.
The companies will merge to operate as Avenzo Therapeutics, backed by a $215 million private placement to advance next-generation oncology pipelines.